Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
Clinical trial NCT04024800 · UNKNOWN
Trial details
- NCT number
- NCT04024800
- Sponsor
- NuGenerex Immuno-Oncology
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-03
- Primary completion
- 2023-06-30
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.